The content reflects information published by altRx (Trinity Healthcare Supply, LLC) and its affiliated entities at the time of publication, alongside FDA published guidance current as of May 2026
This finding indicates that exendin 2029 does not activate GLP-1R (Supplementary Fig
The FDA provided positive end-of-Phase 2 feedback, and Phase 3 initiation is on track for the third quarter of 2026
World CNS Series will capitalise on continued momentum in 2026 with a greater range than ever of intimate, industry-first meetings built to support R&D across neurodegeneration, neuroinflammation, neuropsychiatry and neuromuscular
This chronic inflammation is a hallmark of aging and a fundamental link to various chronic diseases, including cardiovascular and neurodegenerative conditions
Does Ozempic Affect the Face Too